U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H37N3O7S.C2H6O
Molecular Weight 593.7342
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DARUNAVIR ETHANOLATE

SMILES

CC(C)CN(C[C@]([H])([C@]([H])(Cc1ccccc1)N=C(O)O[C@@]2([H])CO[C@]3([H])[C@@]2([H])CCO3)O)S(=O)(=O)c4ccc(cc4)N.CCO

InChI

InChIKey=QWSHKNICRJHQCY-VBTXLZOXSA-N
InChI=1S/C27H37N3O7S.C2H6O/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26;1-2-3/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32);3H,2H2,1H3/t22-,23-,24+,25-,26+;/m0./s1

HIDE SMILES / InChI

Molecular Formula C2H6O
Molecular Weight 46.0685
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C27H37N3O7S
Molecular Weight 547.6657
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23708741 | http://adisinsight.springer.com/drugs/800016726

Darunavir (trade name Prezista) is an orally active bis-furan-sulfonamide inhibitor of human immunodeficiency virus (HIV-1) protease. Darunavir was developed by Tibotec Pharmaceuticals (now Janssen R&D Ireland). Darunavir is indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. The drug is co-administered with low-dose ritonavir and other anti-HIV agents. It is the only antiretroviral that has been registered at two different doses, 800/100 mg once-daily or 600/100 mg twice-daily, allowing its administration throughout the entire course of HIV disease, from naive subjects without any HIV-1 resistance to heavily treatment-experienced subjects with widespread triple-class family resistance.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.5 pM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PREZISTA

Approved Use

PREZISTA is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult patients. PREZISTA is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents.

Launch Date

1.15102083E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5272 ng/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
93026 ng × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
124698 ng × h/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
57055 ng × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
126377 ng × h/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15 h
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
15 h
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5%
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.227
unhealthy, 43
n = 127
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 43
Sex: M+F
Population Size: 127
Sources: Page: p.227
Disc. AE: Headache, Gastrointestinal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Headache (grade 3, 0.79%)
Gastrointestinal disorder NOS (5.51%)
Sources: Page: p.227
3200 mg single, oral
Overdose
Dose: 3200 mg
Route: oral
Route: single
Dose: 3200 mg
Sources: Page: p.22
healthy
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Disc. AE: Drug-induced hepatitis, Hepatitis acute...
AEs leading to
discontinuation/dose reduction:
Drug-induced hepatitis
Hepatitis acute
Cytolytic hepatitis
Reaction skin (grade 1-3)
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Diabetes mellitus
Hyperglycemia
Fat redistribution
Fat tissue increased
Immune reconstitution syndrome
Sources: Page: p.1
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.8
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (grade 1-2, 0.5%)
Sources: Page: p.8
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal disorder NOS 5.51%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.227
unhealthy, 43
n = 127
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 43
Sex: M+F
Population Size: 127
Sources: Page: p.227
Headache grade 3, 0.79%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.227
unhealthy, 43
n = 127
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 43
Sex: M+F
Population Size: 127
Sources: Page: p.227
Cytolytic hepatitis Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Diabetes mellitus Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Drug-induced hepatitis Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Fat redistribution Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Fat tissue increased Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Hepatitis acute Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Hyperglycemia Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Immune reconstitution syndrome Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Stevens-Johnson syndrome Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Toxic epidermal necrolysis Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Reaction skin grade 1-3
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Rash grade 1-2, 0.5%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.8
PubMed

PubMed

TitleDatePubMed
Anti-HIV agents. What the future holds for TMC114.
2005 Aug-Sep
Anti-HIV agents. Interactions with TMC114.
2005 Aug-Sep
Anti-HIV agents. TMC114--an overview.
2005 Aug-Sep
FDA clears HIV drug for patients with resistant virus.
2006 Aug
FDA approves new PI.
2006 Jun
Drug interactions. Interactions with TMC114 and TMC125.
2006 Jun-Jul
The latest in antiretroviral therapy.
2006 Oct
TMC114 approved for resistant patients.
2006 Oct
Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.
2006 Oct 13
Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.
2006 Sep
New HIV treatment.
2006 Sep-Oct
Clinical pharmacokinetics of darunavir.
2007
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
2007
Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
2007
Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
2007
Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
2007
Antiretroviral treatment of HIV infection: Swedish recommendations 2007.
2007
AIDS in the Third World: how to stop the HIV infection?
2007
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
2007 Apr
Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.
2007 Apr 1
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
2007 Apr 7
Development of therapeutics for AIDS: structure-based molecular targeting.
2007 Aug
Darunavir: a second-generation protease inhibitor.
2007 Aug 1
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
2007 Dec
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
2007 Dec 15
Darunavir (TMC114) approved by the FDA.
2007 Feb
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
2007 Feb 19
48-week study results show DRV's staying power.
2007 Jan
Anti-HIV agents. Darunavir and some antidepressants.
2007 Jan
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
2007 Jan
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
2007 Jul 11
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
2007 Jul 7
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
2007 Jul 7
No patient left behind--better treatments for resistant HIV infection.
2007 Jul 7
Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
2007 Jul-Aug
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
2007 Jun
Prezista gets EU approval.
2007 Mar
Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance.
2007 Mar
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.
2007 May
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
2007 May 31
Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patients.
2007 May-Jun
Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
2007 Oct
Quantification of darunavir (TMC114) in human plasma by high-performance liquid chromatography with ultra-violet detection.
2007 Oct 1
Predicting HIV care costs using CD4 counts from clinical trials.
2007 Sep
Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen.
2007 Sep
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
2007 Sep 1
Tipranavir: a new option for the treatment of drug-resistant HIV infection.
2007 Sep 15
Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
2007 Winter
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
2008 Jan
Quality control of protease inhibitors.
2008 Jun
Patents

Sample Use Guides

Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (two 400 mg tablets) taken with ritonavir 100 mg once daily and with food. Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food. Pediatric patients (3 to less than 18 years of age and weighing at least 10 kg): dosage of PREZISTA and ritonavir is based on body weight and should not exceed the treatmentexperienced adult dose. Do not use once daily dosing in pediatric patients. PREZISTA should be taken with ritonavir twice daily and with food.
Route of Administration: Oral
Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human peripheral blood mononuclear cells and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to 5.0 ng/mL). Darunavir demonstrates antiviral activity in cell culture against a broad panel of HIV-1 group M (A, B, C, D, E, F, G), and group O primary isolates with EC50 values ranging from less than 0.1 to 4.3 nM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:34:53 UTC 2021
Edited
by admin
on Fri Jun 25 21:34:53 UTC 2021
Record UNII
33O78XF0BW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DARUNAVIR ETHANOLATE
JAN   MART.   ORANGE BOOK   VANDF   WHO-DD  
Common Name English
PREZISTA
Brand Name English
(3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(ISOBUTYL)AMINO)-1-BENZYL-2-HYDROXYPROPYL)CARBAMATE - ETHANOL (1:1)
Common Name English
DARUNAVIR MONOETHANOLATE [MI]
Common Name English
REZOLSTA
Brand Name English
CARBAMIC ACID, ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-, (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER, COMPD. WITH ETHANOL (1:1)
Common Name English
DARUNAVIR ETHANOLATE [JAN]
Common Name English
DARUNAVIR (AS ETHANOLATE)
Common Name English
TMC114 ETHANOLATE
Common Name English
DARUNAVIR COMPONENT OF SYMTUZA
Common Name English
((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)- CARBAMIC ACID (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER MONOETHANOLATE
Common Name English
DARUNAVIR ETHANOLATE [ORANGE BOOK]
Common Name English
DARUNAVIR ETHANOLATE [VANDF]
Common Name English
SYMTUZA COMPONENT DARUNAVIR
Common Name English
PREZCOBIX COMPONENT DARUNAVIR ETHANOLATE
Brand Name English
DARUNAVIR MONOETHANOLATE
MI  
Common Name English
DARUNAVIR ETHANOLATE [MART.]
Common Name English
DARUNAVIR ETHANOLATE [WHO-DD]
Common Name English
DARUNAVIR ETHANOLATE COMPONENT OF PREZCOBIX
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS REZOLSTA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
NCI_THESAURUS C783
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
EMA ASSESSMENT REPORTS PREZISTA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
Code System Code Type Description
PUBCHEM
23725083
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
PRIMARY
MERCK INDEX
M4099
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
PRIMARY Merck Index
RXCUI
644682
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
PRIMARY RxNorm
FDA UNII
33O78XF0BW
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
PRIMARY
DRUG BANK
DBSALT001338
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
PRIMARY
EVMPD
SUB23573
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
PRIMARY
ChEMBL
CHEMBL1323
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
PRIMARY
CAS
635728-49-3
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
PRIMARY
NCI_THESAURUS
C77389
Created by admin on Fri Jun 25 21:34:53 UTC 2021 , Edited by admin on Fri Jun 25 21:34:53 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
INHIBITOR->TARGET ORGANISM
Related Record Type Details
ACTIVE MOIETY